Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | BMC Immunology

Figure 1

From: CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation

Figure 1

Percentage of peripheral blood CD14+CD16+ monocytes after kidney allograft transplantation. The co-expression of CD14 and CD16 antigens on peripheral blood monocytes was evaluated by flow cytometry in three different groups of patients undergoing kidney allograft transplantation (a-without induction, b-thymoglobulin, c-basiliximab). In patients without the induction therapy (n = 25 ) and those treated with thymoglobulin (n = 28 ), the percentage of CD14+CD16+ monocytes decreased during the first two weeks after the transplantation as compared to only moderate changes observed in subjects treated with basiliximab (n = 18). Analysis of data from flow cytometry was performed by ANOVA with repeated measures and a comparison within groups between two time points by contrasts. *Statistically significant differences.

Back to article page